Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Duchenne Muscular Dystrophy
Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
CP Wire
Thu, 08/30/18 - 10:14 am
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Pfizer Ends Trials for Domagrozumab in Drug for Duchenne Muscular Dystrophy
Thu, 08/30/18 - 09:31 am
Pfizer
domagrozumab
Duchenne Muscular Dystrophy
Mallinckrodt Starts Phase II Duchenne Muscular Dystrophy Study but Will They Meet Recruitment Targets?
Xtalks
Fri, 08/3/18 - 09:44 am
Mallinckrodt
MNK-1411
Duchenne Muscular Dystrophy
clinical trials
FDA slaps a hold on Sarepta’s Duchenne MD study in the wake of stellar early results
Endpoints
Thu, 07/26/18 - 11:53 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
FDA
clinical hold
gene therapy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
CP Wire
Mon, 07/9/18 - 10:51 am
edasalonexent
clinical trials
Duchenne Muscular Dystrophy
Catabasis Plans Ph III Trial for Edasalonexent in Duchenne Muscular Dystrophy
Mon, 07/9/18 - 09:07 am
Catabasis
edasalonexent
Duchenne Muscular Dystrophy
Summit Therapeutics Ditches Duchenne Drug In Wake of Phase 2 Failure
Xconomy
Wed, 06/27/18 - 11:56 am
Summit Therapeutics
ezutromid
clinical trials
Duchenne Muscular Dystrophy
[video/transcript]Sarepta Therapeutics Could Be Onto Something Big
Motley Fool
Mon, 06/25/18 - 07:26 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
Early access to Santhera’s DMD therapy Raxone extended in the UK
Pharma Times
Fri, 06/22/18 - 10:26 pm
UK
Santhera
Raxone
Duchenne Muscular Dystrophy
3 patients add $2.5B to Sarepta's value
Biopharma Dive
Tue, 06/19/18 - 09:45 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
With tantalizing early results, Sarepta’s gene therapy for Duchenne raises hopes for ‘real change’
Stat
Tue, 06/19/18 - 10:55 am
Sarepta Therapeutics
Duchenne Muscular Dystrophy
clinical trials
As Sarepta Preps Data, FDA Lifts Hold on Solid’s Duchenne Gene Therapy
Xconomy
Mon, 06/18/18 - 11:25 am
Duchenne Muscular Dystrophy
Solid Biosciences
Sarepta Therapeutics
SGT-001
Sarepta’s eteplirsen spurned as European regulators turn thumbs down on controversial Duchenne MD drug
Endpoints
Thu, 05/3/18 - 11:14 pm
Sarepta Therapeutics
Duchenne Muscular Dystrophy
eteplirsen
Exondys 51
CHMP
Europe
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
CP Wire
Thu, 04/26/18 - 09:49 am
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Catabasis Pharmaceuticals' Edasalonexent Slowed Duchenne Muscular Dystrophy Disease Progression Through One Year of Treatment
Wed, 04/25/18 - 07:40 pm
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Daiichi Sankyo concedes an early setback on Duchenne MD drug, but doubles down on development
Endpoints
Wed, 04/25/18 - 09:50 am
Daiichi Sankyo
Duchenne Muscular Dystrophy
DS-5141
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
CP Wire
Wed, 04/18/18 - 09:54 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
clinical trials
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy
CP Wire
Wed, 04/18/18 - 09:43 am
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
restructuring
layoffs
Solid Biosciences Provides Update on Clinical Hold of Ph I/II Trial for Duchenne Muscular Dystrophy (DMD)
Wed, 04/18/18 - 09:40 am
Solid Biosciences
SGT-001
Duchenne Muscular Dystrophy
Catabasis Pharmaceuticals Reduces Workforce by 42% to Focus on Developing Edasalonexent for Duchenne Muscular Dystrophy
Tue, 04/17/18 - 06:50 pm
Catabasis
Duchenne Muscular Dystrophy
edasalonexent
Pages
« first
‹ previous
…
4
5
6
7
8
9
10
11
12
…
next ›
last »